Hi everyone, I wanted to take a moment to speak openly and honestly with you about what’s been happening on Facebook and why things are shifting. Over time, Facebook’s increasing censorship has made it extremely difficult to host meaningful, educational conversations there. Content is being restricted, posts are removed without warning, and accounts and groups like ours are being limited or suspended for reasons that often make little sense. Because of this, I’ve made the decision to focus fully to Skool. I want to say thank you — genuinely — for being here. This Skool group is where the real conversations can happen without fear of shadow bans, take downs, or constantly walking on eggshells. Your engagement, questions, and shared experiences are what make this community valuable, and I truly appreciate every one of you choosing to stay connected here. If you previously invited friends or colleagues to the Facebook group, I’d love for you to invite them here to Skool instead. This is now our primary home, and it’s where all updates, discussions, and resources will live going forward. The more aligned people we have here, the stronger and more supportive this community becomes. Thank you for your trust, your presence, and your willingness to adapt as platforms change. I’m excited about what we can build together here — without censorship, without restrictions, and with far more intention. With much gratitude, Kristina Marie 🫶 Please share the Skool invite link: https://www.skool.com/kristinas-peptide-junkies-24-4251/about?ref=b95e744ce4cc491aa244b5ef495d5927

Hope just became a little more affordable for those who insist on using branded only; though new prices may also compel the research world to lower their prices on tirz. as well. Eli Lilly and Company's announcement today — offering Zepbound for $499/month or less for all dosages — is a welcome move for people living with obesity, a disease that has long been misunderstood and under-treated. For many, this still won’t be affordable. But it’s a step in the right direction. • Toward more accessible treatment. • Toward less stigma in care. • Toward recognizing lived experience in policy and practice. We need continued momentum — from pricing reform to insurance coverage to changing how we talk about weight and health.